Navigation Links
Generex Provides Clarification of Facts
Date:6/27/2011

e on a comprehensive strategy to achieve FDA approval of Generex Oral-lyn™.  Today, Dr. Anderson, an independent member of the Generex Board, commented:  "The Company's scientific team is confident that our clinical and regulatory program is designed for success, and we intend to conduct a broader study to include a wider patient population in both type 1 and type 2 diabetes."  The full presentation from the annual meeting of stockholders' is available for viewing on the Generex website at www.generex.com.

Mark Fletcher, Generex President & Chief Executive Officer, stated:  "We have made great strides in establishing  a top notch scientific team at Generex and, as a result, have established a realistic and focused plan to realize success in the future for the largest possible patient population.  The closing of the current Phase III study and the data we obtain from it will further that effort.  Generex Oral-lyn™ has demonstrated efficacy and safety in all of the studies conducted to date."

The June 16 Generex press release stated that the Company's clinical and regulatory plan for Generex Oral-lyn™ will "focus on rapid registration in the North American major markets, with its rapid absorption and sharp peak in plasma insulin concentration mimicking normal insulin secretion, and Generex Oral-lyn™'s short duration of activity reducing the potential for hypoglycemia.  Studies will include a key activity/effect (pharmokinetic/glucodynamic) study using the final formulation and a series of small, well-designed phase 3 studies (potentially conducted as one study with multiple arms)."  Generex management anticipates that these studies will be completed during 2013.  Generex will also focus on studies that will measure Generex Oral-lyn™'s ability to provide metabolic benefits that cannot be achieved with subcutaneously inj
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Results of Annual Stockholders Meeting
2. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
3. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
4. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
5. Generex Announces $3.0 Million Capital Investment
6. Generex Provides Additional Details for October 21st Live Video Webcast
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
10. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
11. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... partner Merck Serono, a division,of Merck KGaA, ... (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia (HPA) ... the European Commission. Merck Serono estimates ...
... DCTH ) today announced the appointment of Roger G. ... Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: COR ), ... disorders. , , (Logo: ... Prior to joining Cortex, Dr. Stoll worked as a consultant ...
... Md., Dec. 9 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,announced ... of ENMD-2076 in refractory,multiple myeloma patients. The study ... Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. ...
Cached Biology Technology:Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 2EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 4
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
... Rome, Italy: Researchers have developed a way of accurately ... blood test. The average difference between the predicted age and ... the menopause was only a third of a year, and ... years. Dr Fahimeh Ramezani Tehrani will tell the 26th ...
... new technology that allows scientists to monitor how individual cells ... researchers have uncovered a much larger spectrum of differences between ... act in a uniform fashion, as was previously thought. ... Markus Covert, PhD, assistant professor of bioengineering and senior author ...
... 27th, 2010 The Elsevier Foundation, TWAS and TWOWS ... scientists from Africa, the Middle East, Asia, Latin America ... was made at the Third World Organization for Women ... Women Scientists in a Changing World, hosted by the ...
Cached Biology News:Researchers develop accurate way to predict the age when women will hit the menopause 2Researchers develop accurate way to predict the age when women will hit the menopause 3Same types of cell respond differently to stimulus, Stanford study shows 2Same types of cell respond differently to stimulus, Stanford study shows 312 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Biology Products: